Cyclerion Therapeutics Partners with Medsteer to Advance Closed-Loop Anesthetic Platform

Reuters01-06
Cyclerion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Partners with Medsteer to Advance Closed-Loop Anesthetic Platform

Cyclerion Therapeutics Inc. has announced a strategic collaboration with Medsteer SAS to advance the development of its closed-loop anesthetic platform. The partnership grants Cyclerion access to Medsteer's proprietary EEG-guided closed-loop control technology, including computational modules, control software, and extensive clinical datasets. This collaboration aims to accelerate the integration of Medsteer's technology into Cyclerion's lead program, CYC-126, which targets treatment-resistant depression. The combined expertise will support the completion of device integration and the initiation of a Phase 2 proof-of-concept study in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclerion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620077-en) on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment